CDX 1401

Drug Profile

CDX 1401

Alternative Names: CDX-1401; DEC-205/NY-ESO-1 vaccine - Celldex

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Gynaecological cancer; Solid tumours

Most Recent Events

  • 29 Jul 2016 Case Comprehensive Cancer Center plans a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease) in USA (NCT02661100)
  • 04 Jun 2016 Adverse events data from a phase II trial in Malignant melanoma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO- 2016)
  • 04 Jun 2016 Celldex establishes CRADA with Cancer Therapy Evaluation Program of the National Cancer Institute for the development of CDX 1401 in Malignant melanoma before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top